Free tool
FAERS Monitor: Zemdri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210303 or its brand name (Zemdri, Plazomicin Sulfate). Reports on generic versions are filed under their own applications.
Reports
3
Serious
2
67% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- acute kidney injury1
- antibiotic level above therapeutic1
- creatinine renal clearance decreased1
- drug effect less than expected1
- gastrointestinal haemorrhage1
- renal failure1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| antibiotic level above therapeutic | 1 | 17328.5 | 3487.1 | 4,321 |
| creatinine renal clearance decreased | 1 | 1752.3 | 353.6 | 437 |
| drug effect less than expected | 1 | 473.2 | 95.5 | 117 |
| gastrointestinal haemorrhage | 1 | 83.9 | 16.9 | 20 |
| renal failure | 1 | 52.8 | 10.7 | 12 |
| acute kidney injury | 1 | 45.8 | 9.2 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.